[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR035064A1 - 3-(1-metil-3-indolil)-4-(1-metil-6-nitro-3-indolil)-1h-pirrol-2,5-diona, en forma amorfa, procesos para prepararla, composicion farmaceutica que la comprende y uso de dicho compuesto en la fabricacion de medicamentos - Google Patents

3-(1-metil-3-indolil)-4-(1-metil-6-nitro-3-indolil)-1h-pirrol-2,5-diona, en forma amorfa, procesos para prepararla, composicion farmaceutica que la comprende y uso de dicho compuesto en la fabricacion de medicamentos

Info

Publication number
AR035064A1
AR035064A1 ARP010104627A ARP010104627A AR035064A1 AR 035064 A1 AR035064 A1 AR 035064A1 AR P010104627 A ARP010104627 A AR P010104627A AR P010104627 A ARP010104627 A AR P010104627A AR 035064 A1 AR035064 A1 AR 035064A1
Authority
AR
Argentina
Prior art keywords
methyl
indolil
compound
nitro
manufacture
Prior art date
Application number
ARP010104627A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR035064A1 publication Critical patent/AR035064A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Extraction Or Liquid Replacement (AREA)

Abstract

3-(1-metil-3-indolil)-4-(1-metil-6-nitro-3-indolil)-1H-pirrol-2,5-diona de fórmula (1), en forma amorfa, que está sustancialmente libre del compuesto cristalino. Dicho compuesto en forma amorfa es farmacéuticamente activo como inhibidor del ciclo celular y por lo tanto es utilizado en el tratamiento de tumores cancerosos. Además, se dan a conocer: procesos para su preparación, composiciones farmacéuticas que la comprenden, y el uso de tal compuesto en la fabricación de medicamentos.
ARP010104627A 2000-10-03 2001-10-01 3-(1-metil-3-indolil)-4-(1-metil-6-nitro-3-indolil)-1h-pirrol-2,5-diona, en forma amorfa, procesos para prepararla, composicion farmaceutica que la comprende y uso de dicho compuesto en la fabricacion de medicamentos AR035064A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23756300P 2000-10-03 2000-10-03

Publications (1)

Publication Number Publication Date
AR035064A1 true AR035064A1 (es) 2004-04-14

Family

ID=22894259

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010104627A AR035064A1 (es) 2000-10-03 2001-10-01 3-(1-metil-3-indolil)-4-(1-metil-6-nitro-3-indolil)-1h-pirrol-2,5-diona, en forma amorfa, procesos para prepararla, composicion farmaceutica que la comprende y uso de dicho compuesto en la fabricacion de medicamentos

Country Status (15)

Country Link
US (4) US6482847B2 (es)
EP (1) EP1366040B1 (es)
JP (3) JP2004510771A (es)
KR (1) KR100554933B1 (es)
CN (1) CN1250541C (es)
AR (1) AR035064A1 (es)
AT (1) ATE447566T1 (es)
AU (2) AU1396502A (es)
BR (1) BRPI0114156B8 (es)
CA (1) CA2423286C (es)
DE (1) DE60140382D1 (es)
ES (1) ES2334012T3 (es)
MX (1) MXPA03002858A (es)
WO (1) WO2002028855A2 (es)
ZA (1) ZA200301593B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482847B2 (en) * 2000-10-03 2002-11-19 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
US20030139373A1 (en) * 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
EP2272501B1 (en) 2002-01-09 2013-03-20 Emisphere Technologies, Inc. Polymorphs of sodium 4-((4-chloro-2-hydroxybenzoyl) amino) butanoate
KR20050011741A (ko) * 2002-04-11 2005-01-29 메드이뮨 백신즈 인코포레이티드 분무 건조에 의한 생물학적 활성 물질의 보존
WO2009052391A1 (en) * 2007-10-19 2009-04-23 Purdue Research Foundation Solid formulations of crystalline compounds
US8268354B2 (en) * 2007-11-07 2012-09-18 Aridis Pharmaceuticals Sonic low pressure spray drying
AU2010247766B2 (en) * 2009-05-12 2015-05-21 Corcept Therapeutics, Inc. Solid forms and process for preparing
US8969588B2 (en) * 2012-06-05 2015-03-03 Gilead Pharmasset Llc Solid forms of an antiviral compound
JP6339364B2 (ja) * 2013-12-27 2018-06-06 カズマパートナーズ株式会社 無定形ブリモニジン酒石酸塩及びその製造方法
GB201502073D0 (en) * 2015-02-09 2015-03-25 Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd HDEG technology
PT108370B (pt) * 2015-03-30 2018-10-25 Hovione Farm S A Processo de preparação de brometo de aclidínio
CN108602847A (zh) * 2015-12-18 2018-09-28 格莱克特生物技术公司 多晶型及方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK278989B6 (sk) * 1988-02-10 1998-05-06 F. Hoffmann-La Roche Ag Substituované pyroly, ich použitie na výrobu lieči
USRE36736E (en) 1989-02-06 2000-06-13 Hoffman-La Roche Inc. Substituted pyrroles
JPH08208478A (ja) * 1994-10-14 1996-08-13 Japan Energy Corp 抗エイズ薬製剤およびその製造方法
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
KR100659411B1 (ko) 1998-03-17 2006-12-18 에프. 호프만-라 로슈 아게 세포 증식 억제를 위한 치환된 비스인돌리말레이미드
US6036736A (en) 1998-04-03 2000-03-14 Wells Manufacturing Company, Inc. Ventilating method and apparatus
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
SE9803261D0 (sv) 1998-09-25 1998-09-25 Siemens Elema Ab Andningsapparat
EP1157030B1 (en) * 1999-03-03 2003-08-27 Eli Lilly And Company Echinocandin/carbohydrate complexes
US6326501B1 (en) 2000-04-19 2001-12-04 Hoffmann-La Roche Inc. Methylation of indole compounds using dimethyl carbonate
US6482847B2 (en) * 2000-10-03 2002-11-19 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability

Also Published As

Publication number Publication date
JP5341331B2 (ja) 2013-11-13
KR20030036872A (ko) 2003-05-09
US6482847B2 (en) 2002-11-19
CN1468231A (zh) 2004-01-14
US20020173534A1 (en) 2002-11-21
KR100554933B1 (ko) 2006-03-03
EP1366040A2 (en) 2003-12-03
ES2334012T3 (es) 2010-03-04
AU1396502A (en) 2002-04-15
US20020173532A1 (en) 2002-11-21
US6469180B1 (en) 2002-10-22
US20020061922A1 (en) 2002-05-23
US6492530B1 (en) 2002-12-10
ATE447566T1 (de) 2009-11-15
MXPA03002858A (es) 2003-07-14
BR0114156A (pt) 2003-07-29
US20020173533A1 (en) 2002-11-21
ZA200301593B (en) 2004-06-22
BRPI0114156B8 (pt) 2021-05-25
WO2002028855A2 (en) 2002-04-11
DE60140382D1 (de) 2009-12-17
WO2002028855A3 (en) 2003-09-12
CA2423286A1 (en) 2002-04-11
EP1366040B1 (en) 2009-11-04
CA2423286C (en) 2008-10-28
CN1250541C (zh) 2006-04-12
US6486329B1 (en) 2002-11-26
AU2002213965B2 (en) 2007-07-19
BRPI0114156B1 (pt) 2018-09-11
JP2012136534A (ja) 2012-07-19
JP2004510771A (ja) 2004-04-08
JP2008056670A (ja) 2008-03-13

Similar Documents

Publication Publication Date Title
UY27368A1 (es) Nuevos compuestos
GT199900203A (es) Composiciones de celecoxib.
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
CY1116103T1 (el) Υποκατεστημενα παραγωγα 1,2,3,4-τετραϋδροϊσοκινολινης
BRPI0914902B8 (pt) Composição farmacêutica para uso no tratamento de mal de parkinson
EA201000643A1 (ru) Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе
DK1157037T3 (da) GCSF-konjugater
AR035064A1 (es) 3-(1-metil-3-indolil)-4-(1-metil-6-nitro-3-indolil)-1h-pirrol-2,5-diona, en forma amorfa, procesos para prepararla, composicion farmaceutica que la comprende y uso de dicho compuesto en la fabricacion de medicamentos
TW200740787A (en) (6-Fluoro-benzo[1,3]dioxolyl)-morpholin-4-yl-methanones
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
AR026064A1 (es) Compuestos de oxabispidina, formulacion farmaceutica, uso de estos compuestos para la manufactura de medicamentos, proceso para la preparacion de estos compuestos, e intermediarios.
ECSP066878A (es) [hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
CL2003002565A1 (es) Compuestos derivados de 3h-quinazolin-4-ona, su proceso de preparacion, composicion farmaceutica que los contiene, y uso en el tratamiento y prevencion de enfermedades mediadas por inhibidores de mao-b, tales como la enfermedad de alzheimer y demenci
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
AR029347A1 (es) Compuesto de adenina, compuesto de isognanina y 2,6-ditioxantina como precursor del mismo, uso de dichos compuestos para preparar una composicion farmaceutica y dicha composicion farmaceutica
SE0301699D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
AR052322A1 (es) Compuestos de n-benzoil-estaurosporina, procesos para su preparacion y composicion farmaceutica
SE0000303D0 (sv) Novel compounds
BRPI9909471B8 (pt) processo para a produção de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil-1h-benzimidazol na forma vi cristalina anidra
NO20064298L (no) Piperazinureaderivater til behandling av endometriose
CO5170463A1 (es) Formas polimorfas de un citrato de azobiciclo [2,2,2]octan- 3-amina y sus composiciones farmaceuticas
BR0000901A (pt) Derivados 4-fenil-4-heteroarilpiperidina
AR026451A1 (es) Compuestos heterociclicos sililados
DE50308492D1 (de) Verbindungen, die faktor xa-aktiv t inhibieren

Legal Events

Date Code Title Description
FC Refusal